Revolutionizing Reperfusion Rates in Ischemic Stroke

RapidPulse™ was the first to patent and validate a precise, pulsed thrombectomy aspiration system

For the ischemic stroke patient, the quality of reperfusion and the speed at which the clot is removed are the keys to recovery. The traditional technologies used to treat ischemic stroke rely on grabbing, and trying to pull out, the offending clot. Our approach of using precise, pulsed aspiration to fully evacuate the clot has been shown to improve reperfusion rates on the first pass.

Our system was designed with the input of the doctors, nurses, and technicians who perform mechanical thrombectomy. The result is the RapidPulse™ Aspiration System which is easy to set up and use. Our precise method of pulsing aspiration using a proprietary and innovative algorithm is meant to enable more complete reperfusion more frequently.

RapidPulse™: More Complete Reperfusion the First Time

First in Human Experience

Researchers used the RapidPulse™ technology to treat 29 patients with ischemic stroke. Using the modified Thrombolysis in Cerebral Infarction (mTICI) scale, these doctors reached mTICI 2c (near perfect reperfusion) or mTICI 3 (compete reperfusion) in 69% of patients as their first pass effect (FPE). In contrast, a recently published study of traditional aspiration achieved FPE mTICI≥2c in only 41.5% of patients*. (*Zaidat, O. O. et al. Endovascular Treatment of Acute Ischemic Stroke With the Penumbra System in Routine Practice: COMPLETE Registry Results Stroke. 2022;53:769–778).

Read the abstract from SNIS 2022

Feasibility Study Results

First in Human Experience

In the second study the results of thirty-five patients treated using the RapidPulse™ Aspiration System were compared to those achieved in 40 patients who had been treated with standard aspiration in the past year. Across five hospitals, 60% of the RapidPulse patients achieved FPE mTICI≥2c on the first pass while only 38.5% of patients who received standard aspiration reached FPE mTICI≥2c.

read the abstract from ESOC 2023

Revolutionizing Reperfusion Rates in Ischemic Stroke

RapidPulse™ was the first to patent and validate a precise, pulsed thrombectomy aspiration system

The RapidPulse™ System is not yet cleared for marketing by the US Food & Drug Administration. It is not available for commercial sale.

The RapidPulse™ Aspiration System

RapidPulse™: More Complete Reperfusion the First Time

First in Human Experience

First in Human Experience

First in Human Experience

Feasibility Study Results

First in Human Experience

First in Human Experience

Revolutionizing Reperfusion Rates in Ischemic Stroke

RapidPulse™ was the first to patent and validate a precise, pulsed thrombectomy aspiration system

The RapidPulse™ System is not yet cleared for marketing by the US Food & Drug Administration. It is not available for commercial sale.

The RapidPulse™ Aspiration System

RapidPulse™: More Complete Reperfusion the First Time

First in Human Experience

First in Human Experience

First in Human Experience

Feasibility Study Results

First in Human Experience

First in Human Experience

This website uses cookies.